123 related articles for article (PubMed ID: 20148756)
1. Rituximab in relapsed aggressive lymphoma: play it again, Sam?
Dreyling M; Schmidt C
Leuk Lymphoma; 2010 Mar; 51(3):355-6. PubMed ID: 20148756
[No Abstract] [Full Text] [Related]
2. Rituximab-CHOP or two-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
Todeschini G; Gelio S; Tecchio C
Ann Oncol; 2004 Mar; 15(3):538-9. PubMed ID: 14998863
[No Abstract] [Full Text] [Related]
3. Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma.
Saito B; Shiozawa E; Usui T; Nakashima H; Maeda T; Hattori N; Shimozuma J; Adachi D; Yamochi-Onizuka T; Takimoto M; Nakamaki T; Ota H; Tomoyasu S
Leukemia; 2007 Dec; 21(12):2563-6. PubMed ID: 17597802
[No Abstract] [Full Text] [Related]
4. [Thyroid malignant lymphoma].
Noh JY; Shimizu T; Ito K
Nihon Rinsho; 2006 May; Suppl 1():482-4. PubMed ID: 16776195
[No Abstract] [Full Text] [Related]
5. Rituximab-CHOP or 2-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
Bernardi D; Giacalone A; Spina M; Tirelli U
Ann Oncol; 2004 Aug; 15(8):1298. PubMed ID: 15277275
[No Abstract] [Full Text] [Related]
6. Severe acute thrombocytopenia following rituximab therapy.
Rosado M; Chao H; Rose M
Leuk Lymphoma; 2007 Nov; 48(11):2239-40. PubMed ID: 17926181
[No Abstract] [Full Text] [Related]
7. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
Howard OM; Gribben JG; Neuberg DS; Grossbard M; Poor C; Janicek MJ; Shipp MA
J Clin Oncol; 2002 Mar; 20(5):1288-94. PubMed ID: 11870171
[TBL] [Abstract][Full Text] [Related]
8. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
9. The treatment of lymphoma complicating autoimmune disease: two birds with one stone?
Mikuls TR
Ann Oncol; 2007 Apr; 18(4):615-8. PubMed ID: 17355949
[No Abstract] [Full Text] [Related]
10. Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14).
Adde M; Enblad G; Hagberg H; Sundström C; Laurell A
Med Oncol; 2006; 23(2):283-93. PubMed ID: 16720929
[TBL] [Abstract][Full Text] [Related]
11. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor.
Bompas E; Velay B; Blay JY
Leuk Lymphoma; 2004 Nov; 45(11):2353-4. PubMed ID: 15512830
[TBL] [Abstract][Full Text] [Related]
13. Complete and durable remission of refractory mantle cell lymphoma with repeated rituximab monotherapy.
Ishiyama K; Takami A; Okumura H; Ozaki J; Shimadoi S; Yamanaka S; Nakao S
Int J Hematol; 2005 May; 81(4):319-22. PubMed ID: 15914363
[TBL] [Abstract][Full Text] [Related]
14. Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era.
Friedberg JW
Clin Cancer Res; 2004 Aug; 10(16):5297-8. PubMed ID: 15328164
[No Abstract] [Full Text] [Related]
15. Lymphoma 2000. The First International Symposium on Biology and Treatment of Aggressive Lymphomas: The stagnation seems to be over.
Pfreundschuh M
Ann Hematol; 2001; 80 Suppl 3():B1-2. PubMed ID: 11757687
[No Abstract] [Full Text] [Related]
16. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
[TBL] [Abstract][Full Text] [Related]
17. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
18. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
[TBL] [Abstract][Full Text] [Related]
19. Intravascular lymphoma presenting with cauda equina syndrome: treated with CHOP and rituxan.
Davis TS
Leuk Lymphoma; 2003 May; 44(5):887-8. PubMed ID: 12802932
[No Abstract] [Full Text] [Related]
20. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
